FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug ...

KalVista Pharmaceuticals KALV saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 62 to 90. Please watch the video at Investors.com - Do Your Stocks Meet ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Equity benchmarks closed higher today, buoyed by a late rally in banking and financial services stocks, with the Nifty ending above the 25,500 level. However, gains were capped by weakness in consumer ...

Get the latest KalVista Pharmaceuticals, Inc. (KALV) stock news and headlines to help you in your trading and investing decisions.

IST, the barometer index, the S&P BSE Sensex, declined 20.01 points or 0.02% to 83,460.19. The Nifty 50 index lost 9.05 points or 0.03% to 25,452.25.